Lexaria Bioscience Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. LEXX has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4.

The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which will be more comprehensive than Lexaria’s previous studies, is expected to involve 60 different volunteers aged between 45 and 70 years. Each of them will use three 150 mg doses of DehydraTECH-CBD every day over six weeks. A recent article notes, “The eventual goal is to seek regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure, and data from this study could be instrumental to that pursuit.”

To view the full article, visit https://cnw.fm/3cpKW

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Image Sourced from Pixabay